DOW JONES27,081.36-879.44 -3.15%
S&P 5003,128.21-97.68 -3.03%
NASDAQ8,965.61-255.67 -2.77%

Catalent To Acquire Cell Therapy Company MaSTherCell Global For $315M

Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, and MaSTherCell

Benzinga · 02/03/2020 12:29

Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, and MaSTherCell Global, Inc., a technology-focused cell and gene therapy contract development and manufacturing organization to leading cell therapy innovators, today announced that Catalent has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. (NASDAQ:ORGS), for an aggregate of $315 million in cash, subject to a customary adjustments.